Abstract 398P
Background
MET exon 14 skipping is a potential driver alteration in lung cancer targetable. Treatment with crizotinib can cause dramatic responses in patients whose cancers have MET exon 14 skipping. The mechanism of acquired resistance to crizotinib for the patients with MET exon 14 skipping NSCLC is not yet fully identified. In this study, we performed mutational profiling in a cohort of MET exon 14 skipping NSCLC patients at diagnosis and following acquired resistance to crizotinib using targeted NGS.
Methods
We screened 2926 patients with NSCLC for MET exon 14 skipping mutation. Among them, 14 patients received crizotinib treatment, and a total of 9 patients with stage IIIb-IV MET exon 14 skipping mutation NSCLC underwent tumor biopsies or blood withdrawal by the time of acquiring resistance to crizotinib, including 3 formalin-fixed paraffin-embedded (FFPE) samples, 4 serum samples and 2 serous effusions. We used targeted NGS to detect the gene status of patients.
Results
In total, we identified 41 genetic alterations with a median of 4.6 mutations per patient. 88.9% of patients still exhibit MET exon 14 skipping mutation, and 22.2% of patients acquired MET point mutations. Besides other known resistance mechanisms, we identified HRAS mutation in 11.1% of patients, and EGFR mutation in 11.1%. Interestingly, we also observed NUP93, MS4A1 and ELAC2 mutations in MET acquired point mutation-negative patients, which were restricted to crizotinib resistance.
Conclusions
MET exon 14 skipping patients acquired resistance mutational profiles were uncovered, and this study also comprehensively depicted the genetic landscape in a Chinese MET exon 14 skipping NSCLC population resistant to crizotinib. Precision methods, such as NGS for oncogenic alteration detection for further study of resistance and suggests corresponding relevant tactics against the challenge of disease progression.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Chun-wei Xu.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
324P - COVID era: Perception of oncologists from a developing nation
Presenter: Rakesh Roy
Session: e-Poster Display Session
325P - Clinical characteristics and outcomes of cancer patients with COVID-19 infection: A retrospective study in a single center in the Philippines
Presenter: Frances Victoria Que
Session: e-Poster Display Session
326P - Management of diffuse large B cell lymphomas in the COVID-19 era
Presenter: David Ng
Session: e-Poster Display Session
327P - COVID-19 in patients with oncohematologic diseases in Kazakhstan
Presenter: Zaure Dushimova
Session: e-Poster Display Session
328P - Impact of COVID-19 pandemic on 30 days colorectal cancer patients mortality undergoing emergency operation
Presenter: Ida Bagus Budhi
Session: e-Poster Display Session
329P - Radiotherapy palliative and COVID-19: Experience of radiotherapy oncology department of Cancer Center Tlemcen, Algeria
Presenter: Asma Mous
Session: e-Poster Display Session
330P - COVID and cancer: Choosing between hammer and anvil
Presenter: Ullas Batra
Session: e-Poster Display Session
331P - The clock stopped with COVID-19 but continued ticking for cancer patients
Presenter: Sasi Shanmugam Senga
Session: e-Poster Display Session
336P - Efficacy of methylcobalamin administered intravenously for chemotherapy-induced peripheral neuropathy (CIPN): A prospective crossover study
Presenter: Jun Chen
Session: e-Poster Display Session
337P - A prospective study about the quality of life and chemotherapy-induced peripheral neuropathy
Presenter: Wala Ben Kridis
Session: e-Poster Display Session